	Т	T		1									once, dui	ing the rep	orting period w	hen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ny financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	as	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
1	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		11	Amount as approved by the Audit Committee.	11		-	-		-	-	-	-	-	-	
2	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		92	Amount as approved by the Audit Committee.	92	-	-	-		-	-	-	-	-	-	-
3	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	c	-	-	-		-	-	-	-	-	-	-
4	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	c	-	-	-		-	-	-	-	-	-	-
5	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	c	-	-	-		-	-	-	-	-	-	-
6	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Purchase of goods or services		57	Amount as approved by the Audit Committee.	57	-	-	-		-	-	-	-	-	-	-
7	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Purchase of goods or services		38	Amount as approved by the Audit Committee.	38	-	-	-		-	-	-	-	-	-	-
8	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		8	Amount as approved by the Audit Committee.	8	-	-	-		-	-	-	-	-	-	-
9	Zydus Lifesciences Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		235	Amount as approved by the Audit Committee.	235	-	-	-		-	-	-	-	-	-	-
10	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Purchase of fixed assets		4	Amount as approved by the Audit Committee.	4	-	-	-		-	-	-	-	-	-	-

	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of	In case monie either party a the tran	s a result of		ny financials inc nake or give loa	lebtedness is i	ncurred to	July bellod w	then such transaction  Details o	of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
11	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of fixed assets		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
12	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	O	-	-	-		-	-	-	-	-	-	-
13	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1		-	-		-	-	-	-	-	-	-
14	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of goods or services		233	Amount as approved by the Audit Committee.	233	-	-	-		-	-	-	-	-	-	-
15	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		5	Amount as approved by the Audit Committee.	5	-	-	-		-	-	-	-	-	-	-
16	Zydus Lifesciences Limited	Vitely Bio LLP	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		10	Amount as approved by the Audit Committee.	10	-	-	-		-	-	-	-	-	-	-
17	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
18	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	o	-	-	-		-	-	-	-	-	-	-
19	Zydus Lifesciences Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		4	Amount as approved by the Audit Committee.	4	-	-	-		-	-	-	-	-	-	-
20	Zydus Lifesciences Limited	International Tax & Investment Consultants- Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-

	T	T		1	ı	1		1					once, dui	ing the rep	orting period w	hen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monion either party a the tran	s a result of		ly financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	as	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
21	Zydus Lifesciences Limited	Sahyadri Hospitals Private Limited	Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1		-	-		-	-	-	-	-	-	-
22	Zydus Lifesciences Limited	TUV India Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	C	-	-	-		-	-	-	-	-	-	-
23	Zydus Lifesciences Limited	Apollo Healthco Limited	Directors and/ or their relatives	Purchase of goods or services		2	Amount as approved by the Audit Committee.	2	-	-	-		-	-	-	-	-	-	-
24	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives			57	Amount as approved by the Audit Committee.	57	-	-	-		-	-	-	-	-	-	-
25	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	336	Amount as approved by the Audit Committee.	336	-	-	-		-	-	-	-	-	-	-
26	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	39	Amount as approved by the Audit Committee.	39	-	-	-		-	-	-	-	-	-	-
27	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	19	Amount as approved by the Audit Committee.	19	-	-	-		-	-	-	-	-	-	-
28	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	116	Amount as approved by the Audit Committee.	116	-	-	-		-	-	-	-	-	-	-
29	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	7	Amount as approved by the Audit Committee.	7	-	-	-		-	-	-	-	-	-	-
30	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	158	Amount as approved by the Audit Committee.	158	-	-	-		-	-	-	-	-	-	-

<u> </u>	_	1		1	1	1	1	1					once, dur	ing the rep	rting period w	hen such transaction	was underta	ıken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monic either party a the tran	s a result of		ny financials inc nake or give loa				Details o	of loans/ inv	estments	
S. No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	as	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
31	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	142	Amount as approved by the Audit Committee.	142	-	-	-		-	-	-	-	-	-	-
32	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	2	Amount as approved by the Audit Committee.	2	-	-	-		-	-	-	-	-	-	-
33	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
34	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Reimburseme nt of Expenses paid	41	Amount as approved by the Audit Committee.	41	-	-	-		-	-	-	-	-	-	-
35	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Reimburseme nt of Expenses Recovered	9	Amount as approved by the Audit Committee.	9	-	-	-		-	-	-	-	-	-	-
36	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		9	Amount as approved by the Audit Committee.	9	-	-	-		-	-	-	-	-	-	-
37	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of goods or services		130	Amount as approved by the Audit Committee.	130	-	-	-		-	-	-	-	-	-	-
38	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	0	Amount as approved by the Audit Committee.	o	-	-	-		-	-	-	-	-	-	-
39	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		374	Amount as approved by the Audit Committee.	374	-	-	-		-	-	-	-	-	-	-
40	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		33,642	Amount as approved by the Audit Committee.	33642	-	-	-		-	-	-	-	-	-	-

	1			1									once, dur	ing the repo	orting period w	hen such transaction	was underta	ıken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ny financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	as	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
41	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		1,165	Amount as approved by the Audit Committee.	1165	-	-	-		-	-	-	-	-	1	-
42	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Sale of goods or services		214	Amount as approved by the Audit Committee.	214	-	-	-		-	-	-	-	-	-	-
43	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Sale of goods or services		184	Amount as approved by the Audit Committee.	184	-	-	-		-	-	-	-	-	-	-
44	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		235	Amount as approved by the Audit Committee.	235	-	-	-		-	-	-	-	-	-	-
45	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Sale of goods or services		565	Amount as approved by the Audit Committee.	565	-	-	-		-	-	-	-	-	-	-
46	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Sale of goods or services		336	Amount as approved by the Audit Committee.	336	-	-	-		-	-	-	-	-	-	-
47	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Sale of goods or services		400	Amount as approved by the Audit Committee.	400	-	-	-		-	-	-	-	-	-	-
48	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Sale of goods or services		169	Amount as approved by the Audit Committee.	169	-	-	-		-	-	-	-	-	-	-
49	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		1,403	Amount as approved by the Audit Committee.	1403	-	-	-		-	-	-	-	-	-	-
50	Zydus Lifesciences Limited	Zydus Takeda Healthcare Private Limited	Joint Ventures	Sale of goods or services		(63)	Amount as approved by the Audit Committee.	-63	-	-	-		-	-	-	-	-	-	-

	1					,			1				once, dur	ing the repo	rting period w	hen such transaction	was underta	ıken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa	lebtedness is i	ncurred to			of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	as	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
51	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		11	Amount as approved by the Audit Committee.	11	-	-	-		-	-	-	-	-	-	-
52	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
53	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of fixed assets		3	Amount as approved by the Audit Committee.		-	-	-		-	-	-	-	-	-	-
54	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of fixed assets		3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-
55	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Sale of goods or services		149	Amount as approved by the Audit Committee.	149	-	-	-		-	-	-	-	-	-	-
56	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of fixed assets		2	Amount as approved by the Audit Committee.	2	-	-	-		-	-	-	-	-	-	-
57	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Sale of goods or services		4	Amount as approved by the Audit Committee.	4	-	-	-		-	-	-	-	-	-	-
58	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		9	Amount as approved by the Audit Committee.	9	-	-	-		-	-	-	-	-	-	-
59	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Sale of goods or services		3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-
60	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		5	Amount as approved by the Audit Committee.	5	-	-	-		-	-	-	-	-	-	-

$\vdash$					ı		1		ı	1				once, du	ing the repo	orting period w	hen such transaction	was underta	iken.	
		Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ny financials inc nake or give loa				Details (	of loans/ inv	estments	
S		Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
6:	1 Z <sub>1</sub>	ydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
6:	2 Z <sub>1</sub>	ydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Sale of goods or services		47	Amount as approved by the Audit Committee.	47	-	-	-		-	-	-	-	-	-	-
6:	3 Z <sub>1</sub>	ydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		283	Amount as approved by the Audit Committee.	283	-	-	-		-	-	-	-	-	-	-
6-	4 Ζ <sub>γ</sub>	ydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		28	Amount as approved by the Audit Committee.	28	-	-	-		-	-	-	-	-	-	-
6	5 Z <sub>1</sub>	ydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Sale of goods or services		59	Amount as approved by the Audit Committee.	59	-	-	-		-	-	-	-	-	-	-
6	5 Z <sub>1</sub>	ydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		4	Amount as approved by the Audit Committee.	4	-	-	-		-	-	-	-	-	-	-
6	7 Z <sub>1</sub>	ydus Lifesciences Limited	Zydus Therapeutics INC	Subsidiary Company	Sale of goods or services		28	Amount as approved by the Audit Committee.	28	-	-	-		-	-	-	-	-	-	-
6	3 Z <sub>1</sub>	ydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		22	Amount as approved by the Audit Committee.	22	-	-	-		-	-	-	-	-	-	-
69	) Z <sub>1</sub>	ydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		80	Amount as approved by the Audit Committee.	80	-	-	-		-	-	-	-	-	-	-
71	) Z <sub>1</sub>	ydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	50	Amount as approved by the Audit Committee.	50	-	-	-		-	-	-	-	-	-	-

<u> </u>				1				1					once, du	ing the rep	orting period w	hen such transaction	was underta	iken.	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related		Value of	In case monic either party a the tran	s a result of		ny financials inc nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
71	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	32	Amount as approved by the Audit Committee.	32	-	-	-		-	-	-	-	-	-	-
72	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	1	Amount as approved by the Audit Committee.	1		-	-		-	-	-	-	-	-	-
73	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	42	Amount as approved by the Audit Committee.	42	-	-	-		-	-	-	-	-	-	-
74	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	10	Amount as approved by the Audit Committee.	10	-	-	-		-	-	-	-	-	-	-
75	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	4	Amount as approved by the Audit Committee.	4	-	-	-		-	-	-	-	-	-	-
76	Zydus Lifesciences Limited	Mr. Pankaj R. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
77	Zydus Lifesciences Limited	Mr. Mukesh M. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	3	-	-	-		-	-	-	-	-	-	-
78	Zydus Lifesciences Limited	Mr. Nitin Raojibhai Desai	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	3	-	-	-		-	-	-	-	-	-	-
79	Zydus Lifesciences Limited	Mr. Apurva S. Diwanji	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	3	-	-	-		-	-	-	-	-	-	-
80	Zydus Lifesciences Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	4	-	-	-		-	-	-	-	-	-	-

														once, dur	ing the rep	orting period w	vhen such transaction	was underta	aken.	
		Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa	lebtedness is i	ncurred to			of loans/ inv		
S		Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
8:	1 Z <sub>y</sub>	ydus Lifesciences Limited	Mr. Bhadresh K. Shah	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	4	-	-	-		-	-	-	-	-	-	-
8:	2 Z <sub>y</sub>	ydus Lifesciences Limited	Mr. Akhil Monappa	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	3	-	-	-		-	-	-	-	-	-	-
83	3 Z <sub>y</sub>	ydus Lifesciences Limited	Mrs. Upasana Konidela	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	3	-	-	-		-	-	-	-	-	-	-
8-	4 Zy	ydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Remuneration		-	N.A.	177	-	-	-		-	-	-	-	-	-	-
8	5 Zy	ydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Remuneration		-	N.A.	79	-	-	-		-	-	-	-	-	-	-
8	6 Zy	ydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Remuneration		-	N.A.	42	-	-	-		-	-	-	-	-	-	-
8	7 Zy	ydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Remuneration		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
8	8 Zy	ydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Interest received		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
8	9 Zy	ydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Interest received	 	-	N.A.	367	-	-	-	<b></b>	-	-	-	-	-	-	-
9	O Zy	ydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.	414	-	-	-		-	-	-	-	-	-	-
9	1 Zy	ydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Interest received		-	N.A.	38	-	-	-		-	-	-	-	-	-	-
9:	2 Zy	ydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Interest received		-	N.A.	394	-	-	-		-	-	-	-		-	-
9:	3 Zy	ydus Lifesciences Limited	Bayer Zydus Pharma Private Limited	Joint Ventures	Interest received		-	N.A.	1	-	-	-	<u> </u>	-	-	-	-	-	-	-
9	4 Zy	ydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Interest paid		-	N.A.	42	-	-			-			-		-	-
9	5 Zy	ydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Interest paid		-	N.A.	882	-	-	-		-	-	-	-	-	-	-
91	6 Zy	ydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Interest paid		-	N.A.	1100	-	-	-		-	-		-	-	-	-
9	7 Zy	ydus Lifesciences Limited	LM Manufacturing India Private Limited	Subsidiary Company	Loan		-	N.A.	4	-	-	-		-	-	Loan	1 Month T Bill + 100 bps	3 Years	Unsecured	Business Purpose
9	B Zy	ydus Lifesciences Limited	LM Manufacturing India Private Limited	Subsidiary Company	Interest received		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
9:	9 Zy	ydus Lifesciences Limited	LM Manufacturing India Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	-	4	-		-	-	-	-	-	-	-
10	00 Zy	ydus Lifesciences Limited	LM Manufacturing India Private Limited	Subsidiary Company	Investment		-	N.A.	0	-	0	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
10	)1 Zy	ydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Investment		-	N.A.	10020	-	10,020	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose

	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind nake or give loa	lebtedness is i	ncurred to	James Bernou	Details (	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
102	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Investment		-	N.A.	900	5,700	6,600	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
103	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Investment		-	N.A.	40	2,950	2,990	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
104	Zydus Lifesciences Limited	Zynext Ventures Pte. Ltd.	Subsidiary Company	Investment		-	N.A.	О	21	-	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
105	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Investment		-	N.A.	6878	198	7,076	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
106	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Loan		-	N.A.	4047	-	-	-		-	-	-	-	-	-	-
107	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Loan		-	N.A.	550	-	-	-		-	-	-	-	-	-	-
108	Zydus Lifesciences Limited	Cadila Healthcare Ltd. Managerial Cadre EPF	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	249	-	-	-		-	-	-	-	-	-	
109	Zydus Lifesciences Limited	Cadila Healthcare Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	350	-	-	-		-	-	-	-	-	-	-
110	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	0	22,324	22,504	-		-	-	-	-	-	-	-
111	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	O	25,702	33,824	-		-	-	-	-	-	-	-
112	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	O	1,035	1,037	-		-	-	-	-	-	-	-
113	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	O	-	196	-		-	-	-	-	-	-	-
114	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	0	-	-		-	-	-	-	-	-	-
115	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	O	149	275	-		-	-	-	-	-	-	-
116	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	625	408	-		-	-	-	-	-	-	-
117	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	46	31	-		-	-	-	-	-	-	-
118	Zydus Lifesciences Limited	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	2	2	-		-	-	-	-	-	-	-

	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of	m	ny financials ind nake or give loa	lebtedness is i	ncurred to	nang period v	vhen such transaction  Details (	of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
119	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	70	89	-		-	-	-	-	-	-	-
120	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	167	283	-		-	-	-	-	-	-	-
121	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	37	44	-		-	-	-	-	-	-	-
122	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	47	48	-		-	-	-	-	-	-	-
123	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans Outstanding	-	N.A.	0	111	210	-		-	-	-	-	-	-	-
124	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Payables - Other than loans	-	N.A.	0	1	2	-		-	-	-	-	-	-	-
125	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.	1		-	-		-	-	-	-	-	-	-
126	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	-	1	-		-	-	-	-	-	-	-
127	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	2	9	-		-	-	-	-	-	-	-
128	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	22	48	-		-	-	-	-	-	-	-
129	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited		Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	0	-	1	-		-	-	-	-	-	-	-
130	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	0	0	-		-	-	-	-	-	-	-
131	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	0	4	-		-	-	-	-	-	-	-

				,									once, dui	ing the rep	orting period w	hen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monic either party a the trans	s a result of		ny financials inc nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
132	Zydus Lifesciences Limited	Cadila Laboratories Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	C	22	-	-		-	-	-	-	-	-	-
133	Zydus Lifesciences Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	C	98	81	-		-	-	-	-	-	-	-
134	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	C	4	12	-		-	-	-	-	-	-	-
135	Zydus Lifesciences Limited	TUV India Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	C	-	0	-		-	-	-	-	-	-	-
136	Zydus Lifesciences Limited	Aleta Hospitals LLP [Formerly known as Zydus Hospitals (Vadodara) LLP]	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	C	0	-	-		-	-	-	-	-	-	-
137	Zydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	C	-	130	-		-	-	-	-	-	-	-
138	Zydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	C	-	24	-		-	-	-	-	-	-	-
139	Zydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	C	-	2	-		-	-	-	-	-	-	-
140	Zydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	C	-	0	-		-	-	-	-	-	-	-
141	Zydus Lifesciences Limited	Mr. Mukesh M. Patel	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	(	-	3	-		-	-	-	-	-	-	-
142	Zydus Lifesciences Limited	Mr. Apurva S. Diwanji	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans Outstanding	-	N.A.	C	-	3	-		-	-	-	-	-	-	-
143	Zydus Lifesciences Limited	Mr. Nitin Raojibhai Desai	Key Managerial Personnel	Any other transaction	Payables - Other than loans Outstanding	-	N.A.	(	-	3	-		-	-	-	-	-	-	-
144	Zydus Lifesciences Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Payables - Other than loans	-	N.A.	(	-	3	-		-	-	-	-	-	-	-

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only

												,				hen such transaction			,
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
145	Zydus Lifesciences Limited	Mr. Bhadresh K. Shah	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	-	3	-		-	-	-	-	-	-	-
146	Zydus Lifesciences Limited	Mr. Akhil Monappa	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	-	2	-		-	-	-	-	-	-	-
147	Zydus Lifesciences Limited	Mrs. Upasana Konidela	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	-	3	-		-	-	-	-	-	-	-
148	Zydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	2	2	-		-	-	-	-	-	-	-
149	Zydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans Outstanding	-	N.A.	0	12,575	12,993	-		-	-	-	-	-	-	-
150	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Receivables - Loans Outstanding	-	N.A.	0	13,698	13,758	-		-	-	-	-	-	-	
151	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Receivables - Loans Outstanding	-	N.A.	0	1,282	1,251	-		-	-	-	-	-	-	-
152	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Receivables - Loans Outstanding	-	N.A.	0	13,989	9,445	-	<u> </u>	-	-	-	-	-	-	-
153	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Receivables - Other than loans	-	N.A.	0	237	142	-		-	-	-	-	-	-	-
154	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than <u>loans</u>	-	N.A.	0	3	7	-		-	-	-	-	-	-	-
155	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	0	45	56	-		-	-	-	-	-	-	-
156	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	5	5	-		-	-	-	-	-	-	-
157	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	30	41	-		-	-	-	-	-	-	-
158	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	-	1	-		-	-	-	-	-	-	-
159	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	286	396	-		-	-	-	-	-	-	-
160	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	4	23	-		-	-	-	-	-	-	-
161	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	19,594	33,153	-		-	-	-	-	-	-	-

	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind nake or give loa	lebtedness is i	ncurred to	Juling period w	Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
162	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	C	4	-	-		-	-	-	-	-	-	-
163	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	C	1,025	1,459	-		-	-	-	-	-	-	-
164	Zydus Lifesciences Limited	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	C	) 21	14	-		-	-	-	-	-	-	-
165	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	c	237	171	-		-	-	-	-	-	-	-
166	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	C	318	651	-		-	-	-	-	-	-	-
167	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	c	534	637	-		-	-	-	-	-	-	-
168	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	c	772	848	-		-	-	-	-	-	-	-
169	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	c	944	1,074	-		-	-	-	-	-	-	-
170	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	c	485	717	-		-	-	-	-	-	-	-
171	Zydus Lifesciences Limited	Etna Biotech S.R.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	C	76	76	-		-	-	-	-	-	-	-
172	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans Outstanding	-	N.A.	c	-	80	-		-	-	-	-	-	-	-
173	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Receivables - Other than loans Outstanding	-	N.A.	c	177	200	-		-	-	-	-	-	-	-
174	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Payables - Other than loans Outstanding	-	N.A.	c	-	3	-		-	-	-	-	-	-	-
175	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Receivables - Other than loans Outstanding	-	N.A.	c	1,522	126	-		-	-	-	-	-	-	-
176	Zydus Lifesciences Limited	Bayer Zydus Pharma Private Limited	Joint Ventures	Any other transaction	Receivables - Other than loans	-	N.A.	C	0	0	-		-	-	-	-	-	-	-

	1	1						1					once, dur	ing the rep	orting period w	hen such transaction	was underta	iken.	
	Details of the party entering into the transaction	Details of the counte	rparty		D. Willer C	Value of the related		Value of	In case monion either party a the tran	s a result of		ny financials inc nake or give loa				Details (	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
177	Zydus Lifesciences Limited	Zydus Takeda Healthcare Private Limited		Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	C	) 112	-	-		-	-	-	-	-	-	-
178	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	C	6	6	-		-	-	-	-	-	-	-
179	Zydus Healthcare Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		2	Amount as approved by the Audit Committee.	2	-	-	-		-	-	-	-	-	-	-
180	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	C	-	-	-		-	-	-	-	-	-	-
181	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	C	-	-	-		-	-	-	-	-	-	-
182	Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	C	-	-	-		-	-	-	-	-	-	-
183	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	C	-	-	-		-	-	-	-	-	-	-
184	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	C	-	-	-		-	-	-	-	-	-	-
185	Zydus Healthcare Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
186	Zydus Healthcare Limited	German Remedies Pharma Private Limited	Subsidiary Company	Sale of goods or services		58	Amount as approved by the Audit Committee.	58	-	-	-		-	-	-	-	-	-	-

	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monic either party a the tran	s a result of		ny financials ind nake or give loa	lebtedness is i	ncurred to	orting period w	hen such transaction  Details o	of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
187	Zydus Healthcare Limited	Bayer Zydus Pharma Private Limited	Joint Ventures	Sale of goods or services		25	Amount as approved by the Audit Committee.	25	-	-	-		-	-	-	-	-	-	-
188	Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Directors and/ or their relatives	Sale of goods or services		13	Amount as approved by the Audit Committee.	13	-	-	-		-	-	-	-	-	-	-
189	Zydus Healthcare Limited	Ramanbhai Foundation		Sale of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
190	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		7	Amount as approved by the Audit Committee.	7		-	-		-	-	-	-	-	-	-
191	Zydus Healthcare Limited	Mr. Harish Sadana	Key Managerial Personnel	Remuneration		-	N.A.	53	-	-	-		-	-	-	-	-	-	-
192	Zydus Healthcare Limited	Mr. Arvind Bothra	Key Managerial Personnel	Remuneration		-	N.A.	13	-	-	-		-	-	-	-	-	-	-
193	Zydus Healthcare Limited	Mr. Sanjay Kumar Gupta	Key Managerial Personnel	Remuneration		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
194	Zydus Healthcare Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.	C	-	-	-		-	-	-	-	-	-	-
195	Zydus Healthcare Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	1	L -	-	-		-	-	-	-	-	-	-
196	Zydus Healthcare Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.	C	-	-	-		-	-	-	-	-	-	-
197	Zydus Healthcare Limited	Mr. Deevyesh J. Radia	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
198	Zydus Healthcare Limited	Dr. Bhavna Doshi	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	1		-	-		-	-	-	-	-	-	-
199	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Interest received		-	N.A.	67	-	-	<u> </u>	<u> </u>	-	-	-	-	-	-	-

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans,
intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only

																when such transaction			u to be disclosed only
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of	In case monic either party a the tran	s a result of		ny financials inc nake or give loa	ebtedness is i	ncurred to			of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
200	Zydus Healthcare Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Interest received		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
201	Zydus Healthcare Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Corporate Social Responsibility (CSR) Expenses	-	N.A.	33	-	-	-		-	-	-	-	-	-	-
202	Zydus Healthcare Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Investment		-	N.A.	548	-	-	-		-	-	-	-	-	-	-
203	Zydus Healthcare Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.	2745	-	-	-	<u></u>	-		Loan	1 Month T Bill +60 bps 1 Month T Bill +65	3 Years	Unsecured	Business Purpose
204	Zydus Healthcare Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.	2500	-	-	-		-	-	Loan	bps	3 Years	Unsecured	Business Purpose
205	Zydus Healthcare Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.	2555	-	-	-		-	-	Loan	1 Month T Bill +35 bps	5 Years	Unsecured	Business Purpose
206	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.	90	-	-	-		-	-	Loan	1 Month T Bill + 90 bps	1 Year	Unsecured	Business Purpose
207	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.	500	-	-	-		-	-	Loan	1 Month T Bill + 90 bps	1 Year	Unsecured	Business Purpose
208	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.	830	-	-	-		-	-	-	-	-	-	-
209	Zydus Healthcare Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Loan		-	N.A.	33	-	-	-		-	-	-	-	-	-	-
210	Zydus Healthcare Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Any other transaction	Share of profit Received	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
211	Zydus Healthcare Limited	Zydus Healthcare Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year (includes Employee's share and contribution)	-	N.A.	255	-	-	-		-	-	-	-	-	-	-
212	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	o	0	0	-		-	-	-	-	-	-	-
213	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than <u>Ioans</u>	-	N.A.	0	0	0	-		-	-	-	-	-	-	-
214	Zydus Healthcare Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	1	2	-		-	-	-	-	-	-	-
215	Zydus Healthcare Limited	Mr. Harish Sadana	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	-	2	-		-	-	-	-	-	-	-
216	Zydus Healthcare Limited	Mr. Arvind Bothra	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	-	1	-		-	-	-	-	-	-	-
217	Zydus Healthcare Limited	Mr. Deevyesh J. Radia	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	O	-	0	-		-	-	-	-	-	-	-

	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ry financials ind nake or give loa	lebtedness is i	ncurred to	braing period w	hen such transaction  Details o	of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
218	Zydus Healthcare Limited	Dr. Bhavna Doshi	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	-	0	-		-	-	-	-	-	-	-
219	Zydus Healthcare Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	-	0	-		-	-	-	-	-	-	-
220	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	2,047	1,769	-		-	-	-	-	-	-	-
221	Zydus Healthcare Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	33	-	-		-	-	-	-	-	-	-
222	Zydus Healthcare Limited	Bayer Zydus Pharma Private Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	7	2	-		-	-	-	-	-	-	-
223	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	2	-	-		-	-	-	-	-	-	-
224	Zydus Healthcare Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	16	6	-		-	-	-	-	-	-	-
225	Zydus Healthcare Limited	Ramanbhai Foundation	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	0	0	0	-		-	-	-	-	-	-	-
226	Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	o	5	5	-		-	-	-	-	-	-	-
227	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		81	Amount as approved by the Audit Committee.	81	-	-	-		-	-	-	-	-	-	-
228	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of fixed assets		3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-
229	Zydus Wellness Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
230	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		1,074	Amount as approved by the Audit Committee.	1074	-	-	-		-	-	-	-	-	-	-

	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the tran	s a result of		ny financials ind nake or give loa	debtedness is i	ncurred to	orting period w	hen such transaction  Details o	of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
231	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		9	Amount as approved by the Audit Committee.	g	-	-	-		-	-	-	-	-	-	-
232	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		181	Amount as approved by the Audit Committee.	181	-	-	-		-	-	-	-	-	-	-
233	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	2	Amount as approved by the Audit Committee.	2	-	-	-		-	-	-	-	-	-	-
234	Zydus Wellness Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.	С	-	-	-		-	-	-	-	-	-	-
235	Zydus Wellness Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.	c	-	-	-		-	-	-	-	-	-	-
236	Zydus Wellness Limited	Mr. Akhil Monappa	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
237	Zydus Wellness Limited	Mr. Kulin Sanjay Lalbhai	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
238	Zydus Wellness Limited	Mr. Srivishnu Raju Nandayala	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
239	Zydus Wellness Limited	Mr. Savyasachi S. Sengupta	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	C	-	-	-		-	-	-	-	-	-	-
240	Zydus Wellness Limited	Mr. Tarun Arora	Key Managerial Personnel	Remuneration		-	N.A.	5	-	-	-		-	-	-	-	-	-	-
241	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Remuneration		-	N.A.	7	-	-	-	ļ	-	-	-	-	-	-	-
242	Zydus Wellness Limited	Mr. Nandish P. Joshi	Key Managerial Personnel	Remuneration		-	N.A.	C	-	-	-		-	-	-	-	-	-	-

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only

													once, dui	ing the rep	orting period v	when such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related			In case monie either party a the trans	s a result of		ny financials inc nake or give loa	lebtedness is i	ncurred to			of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
243	Zydus Wellness Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	1	-	-	-		-	1	-	-	-	-	-
244	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Interest received		-	N.A.	86	-	-	-		-	-	-	-	-	-	-
245	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Interest received		-	N.A.	4	-	-	-		-	-	-	-	-	-	-
246	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.	95	-	-	-		-	-	Loan	1 Month T Bill + 90bps	1 Year	Unsecured	Business Purpose
247	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.	170	-	-	-	<u> </u>	-	-	Loan	1 Month T Bill + 50bps	1 Year	Unsecured	Business Purpose
248	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Loan		-	N.A.	83	-	-	-	<u> </u>	-	-	Loan	6 Month SOFR + 150	2 Years	Unsecured	Business Purpose
249	Zydus Wellness Limited	Zydus Wellness Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	4	-	-	-		-	-	-	-	-	-	-
250	Zydus Wellness Limited	Mr. Tarun Arora	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	C	0	1	-		-	-	-	-	-	-	-
251	Zydus Wellness Limited	Mr. Akhil Monappa	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	c	-	0	-		-	-	-	-	-	-	-
252	Zydus Wellness Limited	Mr. Kulin Sanjay Lalbhai	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	c	-	0	-		-	-	-	-	-	-	-
253	Zydus Wellness Limited	Mr. Savyasachi S. Sengupta	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	c	-	0	-		-	-	-	-	-	-	-
254	Zydus Wellness Limited	Mr. Srivishnu Raju Nandayala	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	c	-	0	-		-	-	-	-	-	-	-
255	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	c	0	1	-		-	-	-	-	-	-	-
256	Zydus Wellness Limited	Mr. Nandish P. Joshi	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	c	0	0	-		-	-	-	-	-	-	-
257	Zydus Wellness Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	c	-	0	-		-	-	-	-	-	-	-
258	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	c	2,463	2,715	-		-	-	-	-	-	-	-
259	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	c	106	190	-	<del> </del>	-	-	-	-	-	-	-

	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa	lebtedness is i	ncurred to	orting period w		of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
260	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	C	71	67	-		-	-	-	-	-	-	-
261	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	C	12	11	-		-	-	-	-	-	-	-
262	Zydus Wellness Products Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	c	-	-	-		-	-	-	-	-	-	-
263	Zydus Wellness Products Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
264	Zydus Wellness Products Limited	Mr. Tarun Arora	Key Managerial Personnel	Remuneration		-	N.A.	25	-	-	-		-	-	-	-	-	-	-
265	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		-	N.A.	68	-	-	-		-	-	-	-	-	-	-
266	Zydus Wellness Products	Zydus Healthcare Limited	Subsidiary	Sale of goods or		-	N.A.	42	-		-		-	-		-	-		-
267	Limited Zydus Wellness Products	Zydus Wellness International	Company Subsidiary	services Sale of goods or			N.A.		<b>.</b>		<del> </del> -		l						
267	Limited Zydus Wellness Products	DMCC	Company Subsidiary	services Sale of goods or			N.A.	·	¥	- 	ļ	 	-			-		- 	
268	Limited	Zydus Healthcare Limited	Company	services		-	N.A.	10	-	-	-		-	-	-	-	-	-	-
269	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	7	-	-	-		-	-	-	-	-	-	-
270	Zydus Wellness Products Limited	Heinz India Private Limited Provident Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	11	-	-	-		-	-	-	-	-	-	
271	Zydus Wellness Products Limited	Heinz India Private Limited Employee Provident Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	17		-	-		-	-	-	-	-	-	-
272	Zydus Wellness Products Limited	Heinz India Private Limited Pension Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	2	-	-	-		-	-	-	-	-	-	

	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ry financials ind nake or give loa	lebtedness is i	ncurred to	Tring period w	then such transaction  Details o	of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
273	Zydus Wellness Products Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	o	-	0	-		-	-	-	-	-	-	-
274	Zydus Wellness Products Limited	Mr. Tarun Arora	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	-	2	-		-	-	-	-	-	-	-
275	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	) 47	81	-		-	-	-	-	-	-	-
276	Zydus Wellness Products Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	0	23	18	-		-	-	-	-	-	-	-
277	German Remedies Pharma Private Limited German Remedies Pharma	Mr. Devanand Kumar Singh	Key Managerial Personnel Subsidiary	Remuneration Sale of goods or		-	N.A.	8	3 -	-	-		-	-	-	-	-	-	-
278	Private Limited	Zydus Healthcare Limited	Company	services		-	N.A.	195	-	-	-		-	-	-	-	-	-	-
279	German Remedies Pharma Private Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Corporate Social Responsibility (CSR) Expenses Share of	-	N.A.	4	-	-	-		-	-	-	-	-	-	-
280	German Remedies Pharma Private Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Any other transaction	profit Received	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
281	German Remedies Pharma Private Limited	Zydus Lifesciences Limited	Parent Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	1,035	1,037	-		-	-	-	-	-	-	-
282	German Remedies Pharma Private Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	-	6	-		-	-	-	-	-	-	-
283	German Remedies Pharma Private Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	) 24	38	-		-	-	-	-	-	-	-
284	Zydus Pharmaceuticals Limited	Mr. Vishal Shah	Key Managerial Personnel	Remuneration		-	N.A.	6	-	-	-		-	-	-	-	-	-	-
285	Zydus Pharmaceuticals Limited	Mr. Jignesh Thosani	Key Managerial Personnel	Remuneration		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
286	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	17	-	-	-		-	-	-	-	-	-	-
287	Zydus Pharmaceuticals Limited	Zydus Worldwide DMCC	Subsidiary	Sale of goods or		-	N.A.	7	-	-	-		-	-	-	-	-	-	-
288	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Company Enterprises significantly influenced by Directors and/ or their relatives	services Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	10	3	-		-	-	-	-	-	-	-

	1	1		1				1					once, du	ing the rep	orting period v	vhen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ny financials inc nake or give loa				Details (	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
289	Zydus Pharmaceuticals Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	C	-	7	-		-	-	-	-	-	-	-
290	Zydus VTEC Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	C	-	-	-		-	-	-	-	-	-	-
291	Zydus Animal Health and	Dialforhealth Unity Limited	Subsidiary	Interest received		-	N.A.	(	-	-	-		-	-	-	-	-	-	-
292	Investments Limited Zydus Animal Health and	Dialforhealth Unity Limited	Company Subsidiary	Loan			N.A.	,		<u> </u>		<b>†</b> -	<del> </del> -		Loan	1 Month T Bill + 120	5 Years	Unsecured	Business Purpose
232	Investments Limited	5.5orneatar only Emilied	Company	20011	Outstanding	<u> </u>		ļ	<del> </del>	<del> </del>	<del> </del>	<del> </del>	<del> </del> -	ļ	20011	bps	Jicais	Jiiscoured	Sasiness i urpose
293	Zydus Animal Health and Investments Limited	Dialforhealth Unity Limited	Subsidiary Company	Any other transaction	Receivables - Loans	-	N.A.	C	-	0	-		-	-	-	-	-	-	-
294	Zydus Animal Health and Investments Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	4	-	-	-		-	-	-	-	-	-	-
295	Zydus Animal Health and Investments Limited	Zydus Lifesciences Limited	Parent Company	Sale of goods or services		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
296	Zydus Animal Health and Investments Limited	ZyVet Animal Health Inc	Subsidiary Company	Sale of goods or services		-	N.A.	610	-	-	-	<u> </u>	-	-	-	-	-	-	-
297	Zydus Animal Health and Investments Limited	Viona Pharmaceuticals INC	Subsidiary	Interest received		-	N.A.	12	-	-	-	<b>+</b>	-	-	-	-	-	-	-
298	Zydus Animal Health and Investments Limited	Mr. Pramod Lokhande	Company Key Managerial Personnel	Remuneration		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
299	Zydus Animal Health and Investments Limited	Mr. Hiren Mistry	Key Managerial Personnel	Remuneration		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
300	Zydus Animal Health and Investments Limited	Mr. Mihir J. Mehta	Key Managerial Personnel	Remuneration		-	N.A.	C	-	-	-		-	-	-	-	-	-	-
301	German Remedies Pharma Private Limited	Dr. Bhavna Doshi	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	C	-	0	-		-	-	-	-	-	-	-
302	German Remedies Pharma Private Limited	Dr. Bhavna Doshi	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	C	-	-	-		-	-	-	-	-	-	-
303	Zydus Animal Health and Investments Limited	Dr. Bhavna Doshi	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to independent directors	-	N.A.	C	-	-	-		-	-	-	-	-	-	-
304	Zydus Animal Health and Investments Limited	Dr. Bhavna Doshi	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	(	-	0	-		-	-	-	-	-	-	-

	Details of the party entering into the transaction	Details of the counte	rparty		2.11.1	Value of the related		Value of	In case monie either party a the trans	s a result of		ny financials ind nake or give loa	lebtedness is i	ncurred to	orting period w	then such transaction Details	of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
305	Zydus Animal Health and Investments Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Corporate Social Responsibility (CSR) Expenses	-	N.A.	14	-	-	-		-	-	-	-	-	-	-
306	Zydus Animal Health and Investments Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.	700	-	-	-		-	-	Loan	1 Month T Bill + 120	3 Years	Unsecured	Business Purpose
307	Zydus Animal Health and nvestments Limited	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	c	-	91	-		-	-	-	-	-	-	-
308	Zydus Animal Health and Investments Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	c	1	1	-		-	-	-	-	-	-	-
309	Zydus Animal Health and Investments Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	c	415	417	-		-	-	-	-	-	-	-
310	Zydus Animal Health and nvestments Limited	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	C	191	493	-		-	-	-	-	-	-	-
311	Zydus Animal Health and nvestments Limited	Zydus Lifesciences Limited	Parent Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	c	0	1	-		-	-	-	-	-	-	-
312	Recon Pharmaceuticals and Investments	Zydus Foundation	Subsidiary Company	Interest received		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
313	Recon Pharmaceuticals and	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		-	N.A.	1	-	-	-	T	-	-	-	-	-	-	-
314	Recon Pharmaceuticals and	Zydus Foundation	Subsidiary Company	Investment		-	N.A.	550	-	-	-	<b></b>	-	-	-	-	-	-	-
315	Zydus Pharmaceuticals (USA) nc.	NAI Laboratories Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	42	-	-	-		-	-	-	-	-	-	-
316	Zydus Pharmaceuticals (USA) Inc.	Navinta III, Inc	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	35	-	-	-		-	-	-	-	-	-	-
317	Zydus Pharmaceuticals (USA) nc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	89	-	-	-		-	-	-	-	-	-	-
318	Zydus Pharmaceuticals (USA) nc.	Navinta NV, Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	282	-	-	-		-	-	-	-	-	-	-
319	Zydus Pharmaceuticals (USA) Inc.	Zydus Healthcare (USA) LLC	Subsidiary Company	Sale of goods or services		-	N.A.	3	-	-		<u> </u>	-	-	-	-	-		-
320	Zydus Pharmaceuticals (USA) nc.	Sentynl Therapeutics Inc.	Subsidiary Company	Sale of goods or services		-	N.A.	3	-	-	-		-	-	-	-	-	-	-

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans,
intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only

											штегеогро	ate acposits, a				hen such transaction			a to be disclosed only
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monic either party a the tran	s a result of		ny financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
321	Zydus Pharmaceuticals (USA)	Viona Pharmaceuticals INC	Subsidiary	Sale of goods or		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
322	nc. Zydus Pharmaceuticals (USA)	ZyVet Animal Health Inc	Company Subsidiary	services Sale of goods or			N.A.		<del> </del>	<del> </del>	<del> </del>		<b></b>		<del> </del>		<del> </del>		
522	nc. Zydus Pharmaceuticals (USA)	Zydus Lifesciences Global FZE	Company Subsidiary	services Purchase of goods or			N.A.		<u> </u>		ļ				ļ				
323	nc.	[UAE]	Company	services		-	N.A.	4	-	-	-		-	-	-	-	-	-	-
324	Zydus Pharmaceuticals (USA) Inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	2	_	-	-		-	-	-	-	-	-	-
325	Zydus Pharmaceuticals (USA) inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Payables - Other than <u>loans</u>	-	N.A.	0	-	2	-		-	-	-	-	-	-	-
326	Zydus Pharmaceuticals (USA) inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimburseme nt of Expenses paid	-	N.A.	7	-	-	-		-	-	-	-	-	-	-
327	Zydus Pharmaceuticals (USA) nc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	2	-	-	-		-	-	-	-	-	-	-
328	Zydus Pharmaceuticals (USA)	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
329	Zydus Pharmaceuticals (USA)	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	4	-	-	-		-	-	-	-	-	-	-
330	Zydus Pharmaceuticals (USA)	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	2	-	-	-		-	-	-	-	-	-	-
331	Zydus Pharmaceuticals (USA) Inc.	Zynext Ventures USA LLC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
332	Zydus Pharmaceuticals (USA) nc.	Mahadev Management Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	46	-	-	-		-	-	-	-	-	-	-
333	Zydus Pharmaceuticals (USA) nc.	Mahadev Management Inc.	Enterprises significantly		Director Sitting Fees	-	N.A.	5	-	-	-		-	-	-	-	-	-	-
334	Zydus Pharmaceuticals (USA)	Zydus Healthcare (USA) LLC	Subsidiary	Interest received		-	N.A.	6	-	-	-		-	-	-	-	-	-	-
335	nc. Zydus Pharmaceuticals (USA)	Sentynl Therapeutics Inc.	Company Subsidiary	Interest received			N.A.	160	<del> </del>	† <u>-</u>	<del> </del>	t			<del> </del>		† <u>-</u>		
	nc. Zydus Pharmaceuticals (USA)		Company Subsidiary	<del> </del>			<b></b>		<del> </del>	<del> </del>	ļ	<del> </del>			<del> </del>		<del> </del>	<del> </del> -	
336	nc. Zydus Pharmaceuticals (USA)	Viona Pharmaceuticals INC	Company Subsidiary	Interest received		-	N.A.	19	-	ļ	ļ	<b></b>	-			-	ļ	-	
337	nc.	ZyVet Animal Health Inc	Company	Interest received		-	N.A.	10	-	<u> </u>	<u> </u>	<u> </u>	-	-	<u> </u>	-	<u> </u>	-	-

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only

													once, du	ing the repo	orting period v	vhen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ny financials inc nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
338	Zydus Pharmaceuticals (USA)	Zydus Therapeutics INC	Subsidiary	Interest received		-	N.A.	117	-	-	-		-	_	-	_	-	-	-
339	Inc. Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Company Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
340	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	-	0	-		-	-	-	-	-	-	-
341	Zydus Pharmaceuticals (USA)	Viona Pharmaceuticals INC	Subsidiary Company	Loan		-	N.A.	224	-	-	-		-	-	Loan	6 Month SOFR + 50 bps	1 Year	Unsecured	Business Purpose
342	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Loan		-	N.A.	1478	-	-	-	<b></b>	-	-	Loan	6 Month SOFR + 50 bps	1 Year	Unsecured	Business Purpose
343	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Loan		-	N.A.	1576	-	-	-		-	-	Loan	6 Month SOFR + 50 bps	1 Year	Unsecured	Business Purpose
344	Zydus Pharmaceuticals (USA) Inc.	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company	Loan		-	N.A.	330	-	-	-		-	-	-	-	-	-	-
345	Zydus Pharmaceuticals (USA) Inc.	Zydus Noveltech Inc.	Subsidiary Company	Loan		-	N.A.	170	-	-	-		-	-	-	-	-	-	-
346	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Loan		-	N.A.	166	-	-	-		-	-	-	-	-	-	-
347	Zydus Pharmaceuticals (USA) Inc.	Zynext Ventures USA LLC	Subsidiary Company	Loan		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
348	Zydus Pharmaceuticals (USA) Inc.	NAI Laboratories Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	20	21	-		-	-	-	-	-	-	-
349	Zydus Pharmaceuticals (USA) Inc.	Navinta III, Inc	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	8	-	-		-	-	-	-	-	-	-
350	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	28	-	-		-	-	-	-	-	-	-
351	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	-	1	-		-	-	-	-	-	-	-
352	Zydus Pharmaceuticals (USA) Inc.	Navinta NV, Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	116	-	-		-	-	-	-	-	-	-
353	Zydus Pharmaceuticals (USA) Inc.	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	9,426	9,134	-		-	-	-	-	-	-	-
354	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables -	-	N.A.	0	4,652	6,257	-		-	-	-	-	-	-	-
355	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Loans Outstanding Receivables - Loans	-	N.A.	0	520	747	-	<del> </del>	-	-	-	-	-	-	-

						•	•		1				once, dui	ing the rep	orting period w	hen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ny financials inc nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
356	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	411	246	-		-	-	-	-	-	-	-
357	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	3,276	4,775	-		-	-	-	-	-	-	-
358	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	70	88	-		-	-	-	-	-	-	-
359	Zydus Pharmaceuticals (USA) Inc.	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	0	0	-	-		-	-	-	-	-	-	-
360	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	o	) 17	8	-		-	-	-	-	-	-	-
361	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	5	4	-		-	-	-	-	-	-	-
362	Zydus Pharmaceuticals (USA) Inc.	Zynext Ventures USA LLC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	0	0	-	-		-	-	-	-	-	-	-
363	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	0	16	42	-		-	-	-	-	-	-	-
364	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	-	N.A.	288	-	-	-		-	-	-	-	-	-	-
365	Zydus Worldwide DMCC	Zydus Healthcare (USA) LLC	Subsidiary Company	Purchase of goods or services		-	N.A.	7	-	-	-		-	-	-	-	-	-	-
366	Zydus Worldwide DMCC	Mr. Pradeep Agnihotri	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
367	Zydus Worldwide DMCC	Mr. Ketan Bhut	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	o	) 1	-	-		-	-	-	-	-	-	-
368	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	4		-	-		-	-	-	-	-	-	-
369	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		-	N.A.	3490	-	-	-		-	-	-	-	-	-	-
370	Zydus Worldwide DMCC	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.	220	-	-	-		-	-	-	-	-	-	-
371	Zydus Worldwide DMCC	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
372	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Interest received		-	N.A.	26	-	-	-	<u> </u>	-	-	-	-	-	-	-
373	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Interest received		-	N.A.	12	-	-	-	<u> </u>	-	-	-	-	-	-	-
374	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Loan		-	N.A.	8	-	-	-	<u> </u>	-	-	Loan	6 Month SOFR+ 80 bps	3 Years	Unsecured	Business Purpose
375	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Loan		-	N.A.	120	-	-	-	<b></b>	-	-	Loan	6 Month SOFR+ 125 bps	3 Years	Unsecured	Business Purpose
376	Zydus Worldwide DMCC	Etna Biotech S.R.L.	Subsidiary Company	Loan		-	N.A.	48	-	<u> </u>	-	<u></u>		-	Loan	6 Month SOFR + 125 bps	5 Years	Unsecured	Business Purpose

Disclosure of related party transactions for the half year/ six months ended March 31, 2024

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only

					1	1		1					once, du	ing the rep	orting period w	hen such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty		Details of	Value of the related party	Remarks on	Value of	In case monie either party a the trans	s a result of	n	ny financials inc nake or give loa				Details	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction		transaction as approved by the audit committee	approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
377	Zydus Worldwide DMCC	Zydus International Private Limited	Subsidiary Company	Interest received		-	N.A.	9	-	-	-		-	-	-	-	-	-	-
378	Zydus Worldwide DMCC	Zydus International Private Limited	Subsidiary Company	Loan		-	N.A.	9521	-	-	-		-	-	Loan	6 Month SOFR+ 125 bps	5 Years	Unsecured	Business Purpose
379	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	344	478	-		-	-	-	-	-	-	-
380	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	872	907	-		-	-	-	-	-	-	-
381	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	-	641	-		-	-	-	-	-	-	-
382	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	-	730	-		-	-	-	-	-	-	-
383	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	5,843	-	-		-	-	-	-	-	-	-
384	Zydus Worldwide DMCC	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	37	-	-		-	-	-	-	-	-	-
385	Zydus Therapeutics INC	Mr. Deven Parmar	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	0	15	1	-		-	-	-	-	-	-	-
386	Viona Pharmaceuticals INC	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
387	Viona Pharmaceuticals INC	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	-	0	-		-	-	-	-	-	-	-
388	Zydus Noveltech Inc.	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
389	Zydus Noveltech Inc.	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	173	-	-		-	-	-	-	-	-	-
390	Hercon Pharmaceuticals LLC	Zydus Noveltech Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	o	341	-	-		-	-	-	-	-	-	-

													once, dur	ring the rep	orting period w	hen such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monion either party a the tran	s a result of		ny financials inc nake or give loa				Details (	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
391	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA)	Subsidiary	Sale of goods or		-	N.A.	18	-	-	-		-	-	_	-	_	-	-
392	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Company Subsidiary	services Sale of goods or			N.A.		<del> </del>		<del> </del> -	<del> </del>	<u> </u>				<del> </del>	<del> </del> -	<del></del>
	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Company Subsidiary Company	services Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.			-	-		-	-	-	-	-	-	-
394	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
395	Zydus Healthcare (USA) LLC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	7	-	-	-		-	-	-	-	-	-	-
396	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	C	208	209	-		-	-	-	-	-	-	-
397	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	C	0	0	-		-	-	-	-	-	-	-
398	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	C	) 1	1	-		-	-	-	-	-	-	-
399	Zydus Healthcare (USA) LLC	Zynext Ventures USA LLC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	C	0	-	-		-	-	-	-	-	-	-
400	Zydus Healthcare (USA) LLC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	C	8	-	-		-	-	-	-	-	-	-
401	ZyVet Animal Health Inc	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	90	-	-	-		-	-	-	-	-	-	-
402	Zydus Wellness International DMCC	Mr. Pradeep Agnihotri	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.	C	-	-	-		-	-	-	-	-	-	-
403	Zydus International Private Limited	RIC Chemicals LTD	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
404	Zydus International Private Limited	Mr. Kamlesh K Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.	(	-	-	-		-	-	-	-	-	-	-
403	Zydus International Private Limited	Mr. Govind Hirani	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.	(	-	-	-		-	-	-	-	-	-	-
406	Zydus International Private Limited	Mr. Upen H. Shah	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.	(	-	-	-	ļ	-	-	-	-	-	-	-
407	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Interest received		-	N.A.	6	· -	-	-	<u> </u>	-	-	-	-	-	-	-
408	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Company	Interest received		-	N.A.	6	-	-	-		-	-	-	-	-	-	-
409	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Interest received		-	N.A.	9	-	-	-	L	-	-	-	-	-	-	-

Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only

L.,				,									once, du	ring the rep	orting period w	vhen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monion either party a the trans	s a result of		y financials ind nake or give loa				Details	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
410	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Interest received		-	N.A.	7	-	-	-		-	-	-	-	-	-	-
411	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Interest received		-	N.A.	465	-	-	-		-	-	-	-	-	-	-
412	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Loan		-	N.A.	80	-	-	-		-	-	Loan	6 Month EURIBOR+ 75 bps	3 Years	Unsecured	Business Purpose
413	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Loan		-	N.A.	81	-	-	-		-	-	-	-	-	-	-
414	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.	5	-	-	-	<b>_</b>	-	-	-	-	-	-	-
415	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Loan		-	N.A.	9567	-	-	-	<b>_</b>	-	-	Loan	6 Month SOFR + 150 bps	5 Years	Unsecured	Business Purpose
416	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	О	-	9,600	-		-	-	-	-	-	-	-
417	Zydus International Private Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Interest received		-	N.A.	21	-	-	-		-	-	-	-	-	-	-
418	Zydus International Private Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	-	17,168	-		-	-	-	-	-	-	-
419	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	0	-	9,603	-		-	-	-	-	-	-	-
420	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	226	237	-		-	-	-	-	-	-	-
421	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	O	331	346	-		-	-	-	-	-	-	-
422	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	329	424	-		-	-	-	-	-	-	-
423	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	302	316	-		-	-	-	-	-	-	-
424	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	16,683	-	-		-	-	-	-	-	-	-
425	Zydus Netherlands B.V.	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Investment		-	N.A.	o	6,181	-	-	T	-	-	Investment	N.A	N.A	Unsecured	Business Purpose
426	Zydus France, SAS	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
427	Zydus Healthcare S.A. (Pty) Ltd	DI Consultancy		Purchase of goods or services		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
428	Zydus Healthcare S.A. (Pty) Ltd	Alidac Pharmaceuticals SA (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	397	398	-		-	-	-	-	-	-	-
	Zydus Healthcare S.A. (Pty) Ltd	Alidac Pharmaceuticals SA (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	48	48	-		-	-	-	-	-	-	-
430	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		-	N.A.	412	-	-	-		-	-	-	-	-	-	-
	Script Management Services	Zydus Healthcare S.A. (Pty) Ltd	Cubridiana	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	0	1	0	-		-	-	-	-	-	-	-

	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ny financials ind nake or give loa	debtedness is i	ncurred to	Julia period v	vhen such transaction  Details	of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
432	Zydus Pharmaceuticals Mexico SA De CV	Zydus Pharmaceuticals Mexico Services Company SA De C.V.	Subsidiary Company	Purchase of goods or services		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
433	Zydus Healthcare Philippines Inc.	RJ Conception Law Office	or their relatives	Purchase of goods or services		-	N.A.	o	-	-	-		-	-	-	-	-	-	-
434	Zynext Ventures Pte. Ltd.	Zynext Ventures USA LLC	Subsidiary Company	Investment		-	N.A.	19	-	19	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
435	Zydus Pharmaceuticals UK Ltd.	Oncosol Limited	Joint Ventures	Loan		-	N.A.	0	-	-	-		-	-	Loan	6 Month SONIA + 200 bps	5 Years	Unsecured	Business Purpose
436	Zydus Pharmaceuticals UK Ltd.	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Loans	-	N.A.	o	-	0	-		-	-	-	-	-	-	-
437	Zydus Pharmaceuticals UK Ltd.	Medsolutions (Europe) Limited	Subsidiary Company	Loan		-	N.A.	О	-	-	-		-	-	Loan	6 Month SONIA + 200 bps	5 Years	Unsecured	Business Purpose
438	Zydus Pharmaceuticals UK Ltd.	Medsolutions (Europe) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	-	0	-		-	-	-	-	-	-	-
439	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Loan		-	N.A.	1606	-	-	-		-	-	Loan	6 Month SONIA + 200 bps	5 Years	Unsecured	Business Purpose
440	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	-	1,626	-		-	-	-	-	-	-	-
441	Zydus Pharmaceuticals UK Ltd.	LiqMeds Worldwide Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	O	-	19	-		-	-	-	-	-	-	-
442	Zydus Pharmaceuticals UK Ltd.	LiqMeds Limited	Subsidiary Company	Loan		-	N.A.	722	-	-	-		-	-	Loan	6 Month SONIA + 200 bps	5 Years	Unsecured	Business Purpose
443	Zydus Pharmaceuticals UK Ltd.	LiqMeds Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	0	-	731	-		-	-	-	-	-	-	-
444	Zydus Pharmaceuticals UK Ltd.	LiqMeds Worldwide Limited	Subsidiary Company	Investment		-	N.A.	3029	-	3,029	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
445	Zydus Pharmaceuticals UK Ltd.	LiqMeds Limited	Subsidiary Company	Investment		-	N.A.	657	-	657	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
446	Zydus Pharmaceuticals UK Ltd.	Medsolutions (Europe) Limited	Subsidiary Company	Investment		-	N.A.	118	-	118	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
447	Zydus Pharmaceuticals UK Ltd.	LiqMeds Lifecare Limited	Subsidiary Company	Investment		-	N.A.	128	-	128	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
448	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Investment		-	N.A.	832	-	832	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
449	Zydus Lifesciences Global FZE [UAE]	Zydus Lifesciences Limited	Parent Company	Purchase of goods or services		-	N.A.	4	-	-	-		-	-	-	-	-	-	-
450	Zydus Lifesciences Global FZE [UAE]	Zydus Lifesciences Limited	Parent Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	0	-	155	-		-	-	-	-	-	-	-
451	Zydus Lifesciences Global FZE [UAE]	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	0	-	222	-		-	-	-	-	-	-	-
452	LiqMeds Worldwide Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Loan		-	N.A.	19	-	-	-		-	-	Loan	6 Month SONIA + 200 bps	5 Years	Unsecured	Business Purpose
453	LiqMeds Worldwide Limited	LM Manufacturing Limited	Subsidiary Company	Sale of goods or services		-	N.A.	6	-	-	-		-	-	-	-	-	-	-
454	LiqMeds Worldwide Limited	Oncosol Limited	Joint Ventures	Sale of goods or services		-	N.A.	0	-		<u> </u>		-			-	-	-	-

	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials inc ake or give loa	lebtedness is i	ncurred to	orting period w	hen such transaction  Details o	of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
455	LiqMeds Worldwide Limited	LiqMeds Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	137	-	-	-		-	-	-	-	-	-	-
456	LM Manufacturing Limited	LiqMeds Limited	Subsidiary Company	Sale of goods or services		-	N.A.	136	-	-	-		-	-	-	-	-	-	-
457	LM Manufacturing Limited	LiqMeds Lifecare Limited	Subsidiary Company	Sale of goods or services		-	N.A.	150	-	-	-		-	-	-	-	-	-	-
458	LM Manufacturing Limited	LiqMeds Worldwide Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	567	-	-	-		-	-	-	-	-	-	-
459	LM Manufacturing Limited	LiqMeds Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	172	-	-	-		-	-	-	-	-	-	-
460	LM Manufacturing Limited	Oncosol Limited		Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
461	LM Manufacturing Limited	LiqMeds Limited	Subsidiary Company	Sale of goods or services		-	N.A.	218	-	-	-		-	-	-	-	-	-	-
462	LiqMeds Limited	LM Manufacturing Limited	Subsidiary Company	Sale of goods or services		-	N.A.	33	-	-	-		-	-	-	-	-	-	-
463	LM Manufacturing India Private Limited	LM Manufacturing Limited	Subsidiary Company	Sale of goods or services		-	N.A.	22	-	-	-		-	-	-	-	-	-	-
464	LiqMeds Worldwide Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	C	-	18	-		-	-	-	-	-	-	-
465	LiqMeds Worldwide Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	c	-	0	-		-	-	-	-	-	-	-
466	LM Manufacturing Limited	LM Manufacturing India Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	C	-	0	-		-	-	-	-	-	-	-
467	LM Manufacturing Limited	LiqMeds Lifecare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	C	-	29	-		-	-	-	-	-	-	-
468	LM Manufacturing Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	c	-	1	-		-	-	-	-	-	-	-
469	LiqMeds Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	c	-	117	-		-	-	-	-	-	-	-
470	LiqMeds Limited	LiqMeds Worldwide Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	C	-	57	-		-	-	-	-	-	-	-
471	Medsolutions (Europe) Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	c	-	0	-		-	-	-	-	-	-	-
472	Zydus Healthcare Limited	Mr. Sanjay Kumar Gupta	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	C	-	0	-		-	-	-	-	-	-	-

Zy	dus Lifesciences Limited

Disclosure of related party transactions for the half year/ six months ended March 31, 2024

Amount in INR Million except stated other

-											Ado	ditional disclosu	re of related	party transa	ctions - applica	able only in case the r			elates to loans.
																•			ed to be disclosed only
													once, du	ing the rep	orting period w	hen such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ny financials ind nake or give loa				Details o	of loans/ inv	estments	
S No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	party	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction	Opening balance	Closing balance	Nature of indebtedn ess [Loans/issuance of debt/any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
47	3 German Remedies Pharma Private Limited	Mr. Devanand Kumar Singh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	C	-	1	-		-	-	-	-	-	-	-
47	4 Zydus Pharmaceuticals Limited	l Mr. Vishal Shah	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	C	-	0	-		-	-	-	-	-	-	-
47	5 Zydus Pharmaceuticals Limited	l Mr. Jignesh Thosani	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	C	-	0	-		-	-	-	-	-	-	-
47	6 Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Sale of Intangible	-	N.A.	26576	-	-	-		-	-	-	-	-	-	-

## Notes:

- 1 Amount mentioned as 0 denotes value less than INR 1 Million.
- 2 Opening and closing balance are not given where there was no transaction of investment during the half year ended March 31, 2024.

  3 Receivables / Payables other than loans represents combined balance against sales / purchase pertaining to goods/ propoerty, plant and equipment / various services / reimbursement of expenses. Hence shown separately.
- 4 Loans given and repaid within reporting period is not disclosed.